[Skip to Content]
[Skip to Content Landing]
Observation
September 2017

Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab

Author Affiliations
  • 1Raúl Carrea Institute for Neurological Research, Department of Neurology, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Buenos Aires, Argentina
JAMA Neurol. 2017;74(9):1143-1144. doi:10.1001/jamaneurol.2017.1456

Alemtuzumab is a humanized monoclonal antibody recently approved for relapsing-remitting multiple sclerosis (MS) treatment. It is highly effective at reducing relapse rate, improving disability outcomes, and decreasing magnetic resonance imaging activity.1 Adverse events include infusion-related reactions, infections, and secondary autoimmune disorders.1,2 We report 2 cases of MS with early neutropenia due to alemtuzumab, an adverse event not previously described, to our knowledge. Both patients signed informed consent.

×